Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 6;13(23):6136. doi: 10.3390/cancers13236136

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Statuses of various targeting immunotherapeutic agents under development in MM. Statuses of different immunotherapeutic formats based on the indicated MM target antigens were summarized from the ClinicalTrials.gov website (data cut-off: 14 October 2021). * CAR T therapy has moved to allogeneic strategies, including BCMA CAR T (NCT05000450 (ALLO-605), NCT04093596 (ALLO-647), NCT04960579 (P-BCMA-ALLO1)) and CS1/SLAMF7 CAR T (NCT04142619 (UCARTCS1A)). ** The BCMA CAR-NK trials are ongoing, including NCT03940833 in phase 1/2 and NCT05008536 in phase 1.